Form 4: Alnylam Pharmaceuticals Director Michael W. Bonney Reports Stock Transactions

Director Michael W. Bonney reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Summary

• Michael W. Bonney, a director at Alnylam Pharmaceuticals, reported transactions involving the company's stock on May 8, 2025.
• Bonney acquired 775 shares represented by restricted stock units (RSUs) at a price of $0.00.
• These RSUs will vest fully on the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• Bonney also acquired a stock option to buy 1,558 shares at an exercise price of $258.35, expiring on May 8, 2035.
• The stock option vests in full upon the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• Bonney also indirectly owns 4,000 shares of Alnylam common stock through the Michael W. Bonney Revocable Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of RSUs and stock options by a director could be interpreted as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect a broader industry trend but is specific to the individual and the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of shares outstanding upon vesting of the RSUs and exercise of the stock options.

Key Dates

Keywords

Alnylam Pharmaceuticals, Michael W. Bonney, Director, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership